Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 163

1.

BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease.

Oster C, Wilde B, Specker C, Sun M, Kribben A, Witzke O, Dolff S.

Int J Mol Sci. 2019 Sep 11;20(18). pii: E4505. doi: 10.3390/ijms20184505.

2.

Expression pattern of co-inhibitory molecules on CMV-specific T-cells in lung transplant patients.

Bessa V, Sun M, Meier M, Zeng Y, Xu S, Dolff S, Sommerwerck U, Korth J, Taube C, Aigner C, Kamler M, Kribben A, Lindemann M, Witzke O, Wilde B.

Clin Immunol. 2019 Sep 6;208:108258. doi: 10.1016/j.clim.2019.108258. [Epub ahead of print]

PMID:
31499181
3.

HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant.

Rohn H, Michita RT, Schramm S, Dolff S, Gäckler A, Korth J, Heinemann FM, Wilde B, Trilling M, Horn PA, Kribben A, Witzke O, Rebmann V.

Cells. 2019 Aug 7;8(8). pii: E847. doi: 10.3390/cells8080847.

4.

Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients.

Lindemann M, Oesterreich S, Wilde B, Eisenberger U, Muelling N, Horn PA, Heinemann FM, Witzke O.

Vaccines (Basel). 2019 Aug 6;7(3). pii: E84. doi: 10.3390/vaccines7030084.

5.

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry.

Korth J, Sertznig H, Moyrer S, Doevelaar AAN, Westhoff TH, Babel N, Witzke O, Kribben A, Dittmer U, Widera M.

J Vis Exp. 2019 Jul 13;(149). doi: 10.3791/59755.

PMID:
31355784
6.

IL-22 production of effector CD4+ T-cells is altered in SLE patients.

Dolff S, Scharpenberg C, Specker C, Kribben A, Witzke O, Wilde B.

Eur J Med Res. 2019 Jul 22;24(1):24. doi: 10.1186/s40001-019-0385-6.

7.

Th17 cells: do regulatory B-cells (Breg) take control in ANCA-vasculitis?

Dolff S, Witzke O, Wilde B.

Rheumatology (Oxford). 2019 Aug 1;58(8):1329-1330. doi: 10.1093/rheumatology/kez133. No abstract available.

PMID:
31329984
8.

Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.

Friebus-Kardash J, Gäckler A, Kribben A, Witzke O, Wedemeyer H, Treckmann J, Herzer K, Eisenberger U.

Transpl Infect Dis. 2019 Jul 15:e13146. doi: 10.1111/tid.13146. [Epub ahead of print]

PMID:
31306562
9.

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from TRANSFORM study.

Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Hernandez Gutierrez MP, Marti AM, Bernhardt P, Pascual J.

Am J Transplant. 2019 Jun 1. doi: 10.1111/ajt.15480. [Epub ahead of print]

PMID:
31152476
10.

Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants.

Gäckler A, Dolff S, Rohn H, Korth J, Wilde B, Eisenberger U, Mitchell A, Kribben A, Witzke O.

BMC Nephrol. 2019 May 14;20(1):167. doi: 10.1186/s12882-019-1340-z.

11.

An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.

Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B; Athena Study Group.

Kidney Int. 2019 Jul;96(1):231-244. doi: 10.1016/j.kint.2019.01.041. Epub 2019 Feb 27.

PMID:
31027892
12.

B-cell dynamics during experimental endotoxemia in humans.

Brinkhoff A, Zeng Y, Sieberichs A, Dolff S, Shilei X, Sun M, Engler H, Benson S, Korth J, Schedlowski M, Kribben A, Witzke O, Wilde B.

Biosci Rep. 2019 May 17;39(5). pii: BSR20182347. doi: 10.1042/BSR20182347. Print 2019 May 31.

13.

Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients.

Dornieden T, Wilde B, Korth J, Werner K, Horn PA, Witzke O, Lindemann M.

J Immunol Res. 2019 Feb 25;2019:3926175. doi: 10.1155/2019/3926175. eCollection 2019.

14.

Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients.

Friebus-Kardash J, Eisenberger U, Ackermann J, Kribben A, Witzke O, Wenzel J, Rohn H, Fiedler M.

Transpl Infect Dis. 2019 Jun;21(3):e13088. doi: 10.1111/tid.13088. Epub 2019 Apr 16.

PMID:
30929308
15.

Evaluation of hemostasis in patients with end-stage renal disease.

Gäckler A, Rohn H, Lisman T, Benkö T, Witzke O, Kribben A, Saner FH.

PLoS One. 2019 Feb 20;14(2):e0212237. doi: 10.1371/journal.pone.0212237. eCollection 2019.

16.

The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation.

Korth J, Anastasiou OE, Bräsen JH, Brinkhoff A, Lehmann U, Kribben A, Dittmer U, Verheyen J, Wilde B, Ciesek S, Witzke O, Widera M.

J Clin Virol. 2019 Apr;113:14-19. doi: 10.1016/j.jcv.2019.02.002. Epub 2019 Feb 10.

PMID:
30771597
17.

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function.

Eisenberger U, Friebus-Kardash J, Guberina H, Kribben A, Witzke O, Willuweit K, Gerken G, Herzer K.

Transplant Direct. 2018 Dec 27;5(1):e419. doi: 10.1097/TXD.0000000000000860. eCollection 2019 Jan.

18.

Th17 cells in renal inflammation and autoimmunity.

Dolff S, Witzke O, Wilde B.

Autoimmun Rev. 2019 Feb;18(2):129-136. doi: 10.1016/j.autrev.2018.08.006. Epub 2018 Dec 17. Review.

PMID:
30572135
19.

The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients.

Lindemann M, Korth J, Sun M, Xu S, Struve C, Werner K, Dornieden T, Horn PA, Witzke O, Wilde B.

Int J Mol Sci. 2018 Dec 8;19(12). pii: E3945. doi: 10.3390/ijms19123945.

20.

Are Adverse Events Induced by the Acute Administration of Calcineurin Inhibitor Cyclosporine A Behaviorally Conditioned in Healthy Male Volunteers?

Kahl AL, Kirchhof J, Petrakova L, Müller J, Laubrock J, Brinkhoff A, Unteroberdörster M, Benson S, Wilde B, Witzke O, Schedlowski M.

Clin Ther. 2018 Nov;40(11):1868-1877. doi: 10.1016/j.clinthera.2018.09.008. Epub 2018 Oct 25.

Supplemental Content

Loading ...
Support Center